coadministered cagrilintide and semaglutide in adults with overweight or obesity Cagrilintide–Semaglutide Type 2 Diabetes CagriSema: a novel dual-pathway approach
CagriSema: a novel dual pathway approach to target obesity and its complications Cagrilintide and semaglutide together drive record weight loss in global trial Coadministered Cagrilintide and Semaglutide, in Adults with Overweight or Obesity. June 22,, 2025. DOI: 10.1056 NEJMoa2502081, CagrilintideSemaglutide in Adults with, Overweight or Obesity and Type 2 In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results
Pay in 4 interest-free payments of $5.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8


